Krystal Biotech to Present at Upcoming Investor Conferences
Krystal Biotech (NASDAQ: KRYS) has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Krystal Biotech (NASDAQ: KRYS) has announced its participation in two upcoming investor conferences. Chairman and CEO Krish S. Krishnan will participate in fireside chats at Citi's 2024 Global Healthcare Conference on December 3 at 8:45 am ET in Miami, Florida, and the 7th Annual Evercore HealthCONx Conference on December 4 at 2:10 pm ET in Coral Gables, Florida. Both presentations will be available via webcast on the company's website's Investors section, with recordings accessible for at least 30 days afterward.
Details
News Market Reaction – KRYS
The recorded move for KRYS in the trading session of this news was +0.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences:
- Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET
- 7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gables, Florida; fireside chat scheduled for 2:10 pm ET
Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s website. Archived versions of the webcasts will also be available on the Investors section of the Company’s website for at least 30 days.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
spaquette@krystalbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.